Le Lézard
Classified in: Health
Subject: MRR

Depression Drugs Market to Surpass US$ 20 Billion by 2031 as Demand for Serotonin-norepinephrine Reuptake Inhibitors Surges

Depression Drugs Manufacturers to Capitalize on High Demand for Tricyclic Antidepressants with Minimal Side Effects

The most recent study from Fact.MR on the market for depression drugs offers a 10-year prediction through 2021 and beyond. The study explains important factors, including drivers, constraints, and opportunities. The report was divided into various segments such as drug type, drug class, disease type, distribution channel, and region to provide the information in an engaging manner.

NEW YORK, Aug. 11, 2022 /PRNewswire/ -- The global depression drugs market was estimated to be worth US$ 13 Billion in 2020. By 2031, sales of depression drugs are expected to surpass US$ 20 Billion and are projected to grow at a CAGR of 4% in the forecast period (2021-2031).


Over the assessment period of 2021 to 2031, demand for serotonin-norepinephrine reuptake inhibitors (SNRIs), which currently holds the largest market share, is anticipated to rise at a CAGR of 2%.

The World Health Organization (WHO) claims that depression, which affects more than 350 million people globally, is one of the main causes of disability. The WHO further mentions that more women are affected by depression than men and about 5% of adults suffer from depression across the globe.

For Critical Insights on this Market, Request for More Info at:


On account of this, key players are focusing on developing novel techniques for the production of tricyclic antidepressants with minimal side effects and long-term outcomes. They are also adopting new ingredients for producing unique medications for treating depression. 

Key Takeaways:

Growth Drivers:


To Gain In-Depth Insights on Depression Drugs Market, Request Methodology at


Competitive Landscape:

Leading producers of depression medications are adopting sustainable growth strategies to broaden their product offerings, maintain their leading positions in international markets, develop their client bases, and gain more market share.

For instance,

Key Companies Profiled by Fact.MR

More Valuable Insights on Depression Drugs Market

In the latest study, Fact.MR offers a detailed study on global depression drugs market for the forecast period of 2021 to 2031. This study also highlights key drivers promoting the sales of depression drugs through detailed segmentation as follows:

By Drug Type:

By Drug Class:

By Disease Type:

By Distribution Channel:

By Region:

Interested to Procure The Data? Inquire here


Key Questions Covered in the Depression Drugs Market Report

Explore Fact.MR's Coverage on the Healthcare Domain

Drug Delivery System Market: The market for drug delivery systems was valued at around US$ 40 Billion in 2022. It is anticipated to grow at a CAGR of more than 7.8% from 2022 to 2032 and reach about US$ 80 Billion by 2032. Innovative drug delivery systems are being developed to address solubility problems and increase the lipid solubility of pharmaceuticals.

Drug Eluting Balloon Catheter Market: Over the next 10 years, it is predicted that the global market for drug-eluting balloon catheters would grow at a healthy CAGR of 18%. Sales of polyurethane drug-eluting balloon catheters are anticipated to exhibit high growth in the next decade.

Drug Discovery Services Market: The market for drug discovery services is anticipated to grow from US$ 19 Billion in 2022 to US$ 50 Billion by 2032. It is likely to exhibit a CAGR of 10.1% from 2022 to 2032. In the upcoming decade, drug discovery services are projected to exhibit high demand due to surging outsourcing of these services to CROs.

Novel Drug Delivery Systems (NDDS) Market: Rising healthcare expenditure, supportive government initiatives, and the presence of key drug delivery system providers are the prime factors that are expected to drive NDDS market growth in this region through 2027.

Drug Discovery Technologies Market: Worldwide demand for drug discovery technologies is anticipated to surge at a CAGR of 8.4% from 2022 to 2026. The AI drug discovery industry is expected to provide lucrative opportunities for new drug discovery technology providers.

Check it Out More Reports by Fact.MR on Healthcare Industry


About Fact.MR

Fact.MR is a market research and consulting agency with deep expertise in emerging market intelligence. Spanning a wide range ? from automotive & industry 4.0 to healthcare, technology, chemical and materials, to even the most niche categories. We are committed to deliver insights that help businesses gain deeper understanding of their target markets. We understand that making sense of the vast labyrinth of data can be overwhelming for businesses. That's why focus on offering insights that can actually make a difference to bottom-lines.

Specialties: Competition Tracking, Customized Research, Syndicated Research, Investment Research, Social Media Research, Business Intelligence, Industry Analysis, Thought Leadership.

Explore All the Industries Reports Here


Mahendra Singh
US Sales Office
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583
E: [email protected]com 
Follow Us: LinkedIn | Twitter | Blog

Logo: https://mma.prnewswire.com/media/713666/FactMR_Logo.jpg

These press releases may also interest you

at 21:02
Neuro Brands, LLC, a leader in the healthier lifestyle beverage space, including the high growth categories of refreshing energy, relaxation, sleep, daily and digestive health, has just announced the purchase of Ape #8585 for 777.0 ETH. Bored Ape...

at 20:32
As part of its commitment to world-class, innovative cancer care for the Tampa Bay region and beyond, Tampa General Hospital (TGH) Cancer Institute has established an adult Bone Marrow Transplant (BMT) and Cell Therapies unit that focuses on treating...

at 20:09
In response to a lawsuit filed by Siri & Glimstad LLP on behalf of the Informed Consent Action Network (ICAN), the CDC has released the first set of data from its v-safe program. V-safe is a smartphone-based program created by CDC specifically for...

at 19:30
Astellas Pharma Inc. (TSE:4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") and Pantherna Therapeutics GmbH (CEO:Klaus Giese, Ph.D., "Pantherna") today announced that the companies have entered into a new technology evaluation agreement for...

at 19:01
New research into the state of safety in UK workplaces has today been published by Draeger Safety UK. Key findings include: Positives: The...

at 19:01
Blue Shield of California today launched a public campaign asking Californians to speak up and make their voices heard by telling the state to undo its failed process for choosing health plans to serve Medi-Cal beneficiaries....

News published on 11 august 2022 at 09:30 and distributed by: